# Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)

> **NCT02865109** · — · NO_LONGER_AVAILABLE · sponsor: **Biogen**

## Conditions studied

- Infantile-onset Spinal Muscular Atrophy

## Interventions

- **DRUG:** Nusinersen

## Key facts

- **NCT ID:** NCT02865109
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02865109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02865109, "Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02865109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*